Phase 2 N=70 Study of RSVpreF Vaccination and RSV Challenge in Healthy Adults
Respiratory Syncytial Virus Infections
Primary: Area Under the Viral Load-time Curve (VL-AUC) of RSV — 0.00; 96.65 h*log10 PFU/mL
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=21 Ketamine for the Treatment of Opioid Use Disorder and Depression
Depression · Opioid-use Disorder · Opioid Abuse
Primary: Percentage of Individuals Completing Informed Consent — 34 Participants
Phase 2 N=32 A Study to Assess the Safety and Efficacy of Oral Insulin in T2DM Patients With Nonalcoholic Steatohepatitis (NASH)
Diabetes Mellitus, Type 2 · NASH - Nonalcoholic Steatohepatitis
Primary: Number of Treatment-Emergent Adverse Events — 0; 2 Adverse Events
Phase 2 N=369 A Phase 2b Study Evaluating the Safety and Efficacy of AR-15512 Ophthalmic Solution for the Treatment of Dry Eye Disease
Dry Eye Disease
Primary: Least Squares Mean Change From Baseline in Pre-CAE (Controlled Adverse Environment) Ocular Discomfort Score (ODS) on a Visual Analogue Scale at Day 28 — -15.3; -11.0…
Phase 2 N=8 Study to Evaluate the Efficacy and Safety of Pemigatinib in Participants With Relapsed or Refractory Advanced Non-Small Cell Lung Cancer With an FGFR Alteration
Non-Small Cell Lung Cancer (NSCLC)
Primary: Objective Response Rate (ORR) in Cohort A — 33.3 percentage of participants
Phase 2 N=152 Study to Assess the Efficacy of VLY-686 in Relieving Symptoms of Gastroparesis
Gastroparesis
Primary: Change From Baseline in Average Nausea Severity — -1.25; -0.73 score on a scale (change from baseline) — p=.0099
Phase 2 N=12 Effect of Perampanel on Peritumoral Hyperexcitability in HGG
Glioma, Malignant · Surgery · Seizures
Primary: Peritumoral HFO Rate — 2.5; 1.4 HFOs per minute
Phase 2 N=23 Tagraxofusp in Patients With Blastic Plasmacytoid Dendritic Cell Neoplasm or Acute Myeloid Leukemia
Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) · Acute Myeloid Leukemia (AML)
Primary: MTD (Stage 1) — 12; 12; 16 µg/kg/day
Phase 2 N=2 Long-Term Followup and/or Thalidomide Maintenance Therapy for Patients Enrolled on Clinical Trial 20030165
Mantle Cell Lymphoma · Non-Hodgkin's Lymphoma
Primary: Progression-free Survival (PFS) — NA years
Phase 2 N=80 Pembrolizumab in Combination With Cisplatin and Intensity Modulated Radiotherapy (IMRT) in Head and Neck Cancer
Head and Neck Squamous Cell Carcinoma
Primary: Progression-free Survival at ≤12 Months — 71; 83 percentage of patients
Phase 2 N=93 Study to Evaluate the Efficacy and Safety of Once-Weekly Oral NBI-1065846 in the Treatment of Anhedonia in MDD
Anhedonia · Major Depressive Disorder
Primary: Change in Anhedonia Severity, as Measured by Change in DARS Score From Baseline to Day 57 — 17.4; 13.5 units on a scale — p=0.8663
Phase 2 N=163 A Study to Evaluate the Effectiveness and Safety of SKI-O-703 in Patients Experiencing Active Rheumatoid Arthritis Despite Treatment With Conventional Therapies.
Rheumatoid Arthritis
Primary: Change in Disease Activity Score — -0.95; -0.91; -1.06; -1.15 score on a scale
Phase 2 N=122 Bryostatin Treatment of Moderately Severe Alzheimer's Disease
Alzheimer Disease
Primary: Safety: Treatment-emergent Adverse Events and Serious Adverse Events for All Randomized Subjects Who Received Any Study Medication — 15; 13; 4; 4 number of events
Phase 2 N=130 A Study of JNJ 73763989+JNJ 56136379+Nucleos(t)Ide Analog (NA) Regimen Compared to NA Alone in e Antigen Negative Virologically Suppressed Participants With Chronic Hepatitis B Virus Infection
Hepatitis B, Chronic
Primary: Percentage of Participants With Hepatitis B Surface Antigen (HBsAg) Seroclearance at Week 72 Without Restarting NA Treatment — 0.0; 0.0 Percentage of participants
Phase 2 N=6 MCS110 With BRAF/MEK Inhibition in Patients With Melanoma
Melanoma
Primary: Number of Participants With Dose Limiting Toxicities (DLT) [Phase I] — 1 Participants